These findings suggest that SIRT1 might serve as a molecular therapeutic target for 1,25(OH)2D via the NLRP3 inflammasome inhibition in NAFLD. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.